Retatrutide appears to be a new medication in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By stimulating these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately leads to significant slimming. While research is ong